PT935607E - Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes - Google Patents

Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes

Info

Publication number
PT935607E
PT935607E PT97938386T PT97938386T PT935607E PT 935607 E PT935607 E PT 935607E PT 97938386 T PT97938386 T PT 97938386T PT 97938386 T PT97938386 T PT 97938386T PT 935607 E PT935607 E PT 935607E
Authority
PT
Portugal
Prior art keywords
proteins
physius
monumental
class
multivalent soluble
Prior art date
Application number
PT97938386T
Other languages
English (en)
Inventor
Jack L Strominger
Kai W Wucherpfennig
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of PT935607E publication Critical patent/PT935607E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT97938386T 1996-08-16 1997-08-15 Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes PT935607E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16

Publications (1)

Publication Number Publication Date
PT935607E true PT935607E (pt) 2004-12-31

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97938386T PT935607E (pt) 1996-08-16 1997-08-15 Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes

Country Status (11)

Country Link
EP (1) EP0935607B1 (pt)
JP (1) JP2000516470A (pt)
AT (1) ATE272070T1 (pt)
AU (1) AU730457B2 (pt)
CA (1) CA2263195A1 (pt)
DE (1) DE69730038T2 (pt)
DK (1) DK0935607T3 (pt)
ES (1) ES2221065T3 (pt)
NZ (1) NZ333915A (pt)
PT (1) PT935607E (pt)
WO (1) WO1998006749A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889964A1 (en) 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999042597A1 (en) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
BR9910253A (pt) * 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
JP2004536554A (ja) 2000-10-10 2004-12-09 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ Ｍｈｃ陽性細胞からの比較リガンドマッピング
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
EP1353950A2 (en) * 2000-12-18 2003-10-22 William H. Hildebrand Method and apparatus for the production of antigens and uses thereof
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CA2860678A1 (en) * 2012-01-06 2013-07-11 Oregon Health & Science University Partial mhc constructs and methods of use
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3052526A4 (en) 2013-10-03 2017-04-19 Oregon Health & Science University Recombinant polypeptides comprising mhc class ii 1 domains
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
KR20260011774A (ko) * 2016-11-09 2026-01-23 유티아이 리미티드 파트너쉽 재조합 pMHC II형 분자
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
JP7436372B2 (ja) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ 自己免疫性疾患を治療する方法
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
EP0997477B1 (en) * 1994-07-29 2006-03-15 Sunol Molecular Corporation MHC complexes and uses thereof

Also Published As

Publication number Publication date
CA2263195A1 (en) 1998-02-19
AU730457B2 (en) 2001-03-08
WO1998006749A3 (en) 1998-06-11
ATE272070T1 (de) 2004-08-15
NZ333915A (en) 2000-11-24
WO1998006749A2 (en) 1998-02-19
DE69730038D1 (de) 2004-09-02
ES2221065T3 (es) 2004-12-16
DE69730038T2 (de) 2004-11-25
JP2000516470A (ja) 2000-12-12
EP0935607B1 (en) 2004-07-28
DK0935607T3 (da) 2004-12-06
AU4072397A (en) 1998-03-06
EP0935607A2 (en) 1999-08-18

Similar Documents

Publication Publication Date Title
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE69933216D1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EP0832105A4 (en) IMMUNOGENIC PEPTIDES OF PROSTATE-SPECIFIC ANTIGENS
MA24638A1 (fr) Vaccin
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
DE69837283D1 (de) Verwendung von einem phospatidylserine/polypeptide konjugat um autoimmunität hervorzurufen in der behandlung von krebs
FI895382A0 (fi) Uretan-skyddade aminosyra-n -karboxianhydrider.
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
EA200000311A1 (ru) Новый белок иммунной системы - кау
EP1102596A4 (en) PEPTIDANTAGONISTS OF ZONULIN AND METHODS FOR THE USE THEREOF
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
BG102362A (en) New derivatives of amino acids, their preparation and application
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
EP0209543A4 (en) FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
BR0110577A (pt) Decorina transgenicamente produzida
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
GB9501826D0 (en) Polypeptide fragments
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
EP1136555A4 (en) TUMORANT PROTEIN ART-1 AND TUMORANT PEPTIDES THEREOF